This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of these benzodiazepine derivatives, and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with central nervous system disorders (CNS). In particular, the invention relates to the use of the α5-containing GABA receptor agonist (for example, the positive allosteric modulator of the α5-containing GABA receptor) described in the invention in treating a cognitive impairment associated with central nervous system disorders (CNS) in a subject in need of this treatment or at risk of cognitive impairment, including, without limitation, in subjects at risk of developing or suffering from age-related cognitive impairment, mild cognitive n arrest (MCI), amnesic mild cognitive impairment (aMCI), age-related memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal Alzheimer's disease, post-traumatic stress disorder (PTSD), schizophrenia, schizophrenia, schizophrenia, prodromal period, stress disorder (PTSD), schizophrenia, schizophrenia bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer therapy, mental retardation, Parkinson's disease (PD), autistic spectrum disorders, fragile X chromosome syndrome, th Rhett, compulsive behavior and addiction.Это изобретение относится к производным бензодиазепина, композициям, включающим терапевтически эффективные количества этих производных бензодиазепина, и к способам применения этих производных или композиций при лечении когнитивного нарушения, связанного с расстройствами центральной нервной системы (CNS). В частности, изобретение относится к применению агониста α5-содержащего рецептора GABAA (например, позитивного аллостерического модулятора α5-содержащего рецептора GABAA), описанного в изобретении, при лечении когнитивного нарушения, связанного с расстройствами центральной нервно
